Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Vir Biotechnology Inc (VIR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vir Biotech's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.30 -0.05    -1.15%
08/08 - Closed. Currency in USD
After Hours
4.30
-0.00
-0.00%
21:35:46 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,544,577
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 4.25 - 4.49
Vir Biotech 4.30 -0.05 -1.15%

Vir Biotechnology Inc Company Profile

 
Get an in-depth profile of Vir Biotechnology Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

408

Equity Type

ORD

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Contact Information

Address 1800 Owens Street Suite 900
San Francisco, 94158
United States
Phone 415 906 4324
Fax -

Top Executives

Name Age Since Title
Vicki L. Sato 75 2016 Independent Chairman
Marianne De Backer 55 2023 CEO & Director
Robert Taylor Nelsen 63 2016 Independent Director
George A. Scangos 77 2017 Director
Charles M. Rice - - Scientific Advisor
Susanna Naggie - - Scientific Advisor
Jeffrey A. Bluestone 72 - Scientific Advisor
Thomas O. Daniel 71 2017 Scientific Advisor
George H. Poste 81 - Scientific Advisor
Francis V. Chisari - - Scientific Advisor
Jeffrey V. Ravetch 74 - Scientific Advisor
Emilio A. Emini 72 2015 Scientific Advisor
Sona Saira Gonsalves Ramasastry 49 2019 Independent Director
Jeffrey S. Hatfield 67 2020 Independent Director
Robert J. More 57 2016 Independent Director
Charles Elliott Sigal 73 2020 Independent Director
Janet Napolitano 67 2020 Independent Director
Norbert W. Bischofberger 69 2024 Independent Director
Ramy Farid 60 2024 Independent Director
Louis J. Picker - - Co-Founder & Scientific Advisor
Lawrence Corey 77 2016 Co-Founder & Scientific Advisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VIR Comments

Write your thoughts about Vir Biotechnology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email